Advances in surgical treatment for valvular heart disease: a narrative review of 2025 studies.

J Thorac Dis · 2026 · PMC13266806 · PMID 42306693

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

However, in the BAV subgroup, TAVR showed a trend towards higher event rates (20.4% vs. 7.8%, HR 2.9), whereas outcomes were comparable in the tricuspid aortic valve subgroup.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.